OBJECTIVE: To investigate the efficacy of etanercept in improving the symptoms and underlying inflammation in patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Fifteen patients with TRAPS were enrolled in a prospective, open-label, dose-escalation study. Patients recorded attacks, symptom severity, and use of ancillary medications in a daily diary. Blood samples were collected during each period and measured for levels of acute-phase reactants. Between 7 years and 9 years after the conclusion of the initial study, patients completed a followup survey and were evaluated to determine the long-term outcome of etanercept treatment. RESULTS: Etanercept treatment significantly attenuated the total symptom score and reduced the frequency of symptoms. Etanercept also reduced levels of acute-phase reactants, particularly during asymptomatic periods. During a 10-year followup period, patients continued to receive etanercept for a median of 3.3 years, with a number of patients switching to anti-interleukin-1β receptor therapy or not receiving biologic agents, most frequently citing injection site reactions and lack of efficacy as reasons for discontinuation. However, patients continuing to receive etanercept had reduced symptoms at followup. CONCLUSION: Etanercept reduces symptoms and serum levels of inflammatory markers of TRAPS in a dose-dependent manner, but does not completely normalize symptoms or acute-phase reactant levels. Although long-term adherence to etanercept is poor, continuing to receive etanercept may provide continued symptomatic benefit.
OBJECTIVE: To investigate the efficacy of etanercept in improving the symptoms and underlying inflammation in patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Fifteen patients with TRAPS were enrolled in a prospective, open-label, dose-escalation study. Patients recorded attacks, symptom severity, and use of ancillary medications in a daily diary. Blood samples were collected during each period and measured for levels of acute-phase reactants. Between 7 years and 9 years after the conclusion of the initial study, patients completed a followup survey and were evaluated to determine the long-term outcome of etanercept treatment. RESULTS: Etanercept treatment significantly attenuated the total symptom score and reduced the frequency of symptoms. Etanercept also reduced levels of acute-phase reactants, particularly during asymptomatic periods. During a 10-year followup period, patients continued to receive etanercept for a median of 3.3 years, with a number of patients switching to anti-interleukin-1β receptor therapy or not receiving biologic agents, most frequently citing injection site reactions and lack of efficacy as reasons for discontinuation. However, patients continuing to receive etanercept had reduced symptoms at followup. CONCLUSION: Etanercept reduces symptoms and serum levels of inflammatory markers of TRAPS in a dose-dependent manner, but does not completely normalize symptoms or acute-phase reactant levels. Although long-term adherence to etanercept is poor, continuing to receive etanercept may provide continued symptomatic benefit.
Authors: Anna Simon; Evelien J Bodar; Jeroen C H van der Hilst; Jos W M van der Meer; Theo J W Fiselier; Marcel P J M Cuppen; Joost P H Drenth Journal: Am J Med Date: 2004-08-01 Impact factor: 4.965
Authors: N Quillinan; G Mannion; A Mohammad; R Coughlan; L J Dickie; M F McDermott; D McGonagle Journal: Ann Rheum Dis Date: 2011-03-06 Impact factor: 19.103
Authors: Michael E Weinblatt; Joan M Bathon; Joel M Kremer; Roy M Fleischmann; Michael H Schiff; Richard W Martin; Scott W Baumgartner; Grace S Park; Edward L Mancini; Mark C Genovese Journal: Arthritis Care Res (Hoboken) Date: 2010-10-18 Impact factor: 4.794
Authors: M A Pelagatti; A Meini; R Caorsi; M Cattalini; S Federici; F Zulian; G Calcagno; A Tommasini; G Bossi; M P Sormani; F Caroli; A Plebani; I Ceccherini; A Martini; M Gattorno Journal: Arthritis Rheum Date: 2011-04
Authors: Keith M Hull; Elizabeth Drewe; Ivona Aksentijevich; Harjot K Singh; Kondi Wong; Elizabeth M McDermott; Jane Dean; Richard J Powell; Daniel L Kastner Journal: Medicine (Baltimore) Date: 2002-09 Impact factor: 1.889
Authors: M E Weinblatt; J M Kremer; A D Bankhurst; K J Bulpitt; R M Fleischmann; R I Fox; C G Jackson; M Lange; D J Burge Journal: N Engl J Med Date: 1999-01-28 Impact factor: 91.245
Authors: Ariel C Bulua; Anna Simon; Ravikanth Maddipati; Martin Pelletier; Heiyoung Park; Kye-Young Kim; Michael N Sack; Daniel L Kastner; Richard M Siegel Journal: J Exp Med Date: 2011-01-31 Impact factor: 14.307
Authors: Francesco La Torre; Maurizio Muratore; Antonio Vitale; Fulvio Moramarco; Laura Quarta; Luca Cantarini Journal: Rheumatol Int Date: 2015-06-06 Impact factor: 2.631
Authors: Heiyoung Park; Ariel Bulua Bourla; Daniel L Kastner; Robert A Colbert; Richard M Siegel Journal: Nat Rev Immunol Date: 2012-07-25 Impact factor: 53.106